CVS Health joined returning backers that could include SoftBank Vision Fund 2, MassMutual Ventures, Jianke and Aviva in a round valuing the digital care service at $1.3bn.
US-headquartered remote care technology developer Biofourmis secured $300m in series D funding yesterday from investors including pharmacy chain operator CVS Health at a $1.3bn valuation.
Growth equity firm General Atlantic led the round, which also featured undisclosed existing investors. It brought the total raised by Biofourmis to $445m, the company said.
Founded in Singapore in 2015, Biofourmis has built an artificial intelligence-driven software platform that helps healthcare professionals analyse medical data to provide specialist care for patients suffering from chronic…
